Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma (multiple letters)

Stefan Gluck, Jacques Bonneterre, Aman Buzdar, Jean Marc Nabholtz, John Robertson, Beat Thrlimann, Mikael Von Euler, Tarek Sahmoud, Mark Steinberg, Alan Webster

Research output: Contribution to journalLetter

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)2442-2443
Number of pages2
JournalCancer
Volume95
Issue number11
DOIs
StatePublished - Dec 1 2002

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gluck, S., Bonneterre, J., Buzdar, A., Nabholtz, J. M., Robertson, J., Thrlimann, B., Von Euler, M., Sahmoud, T., Steinberg, M., & Webster, A. (2002). Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma (multiple letters). Cancer, 95(11), 2442-2443. https://doi.org/10.1002/cncr.10962